X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse GSK Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs MYLAN (US) - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GSK PHARMA   MYLAN
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
MYLAN
Dec-14
GSK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2,7604,254-   
Low Rs2,0402,998-   
Sales per share (Unadj.) Rs339.01,456.2-  
Earnings per share (Unadj.) Rs41.4175.4-  
Cash flow per share (Unadj.) Rs45.9282.4-  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs242.9723.9-  
Shares outstanding (eoy) m84.70378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x7.12.5 284.3%   
Avg P/E ratio x57.920.7 280.4%  
P/CF ratio (eoy) x52.312.8 407.2%  
Price / Book Value ratio x9.95.0 197.3%  
Dividend payout %84.50-   
Avg Mkt Cap Rs m203,2801,371,817 14.8%   
No. of employees `000NA25.0 0.0%   
Total wages/salary Rs m5,2340-   
Avg. sales/employee Rs ThNM22,039.1-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,655.0-  
INCOME DATA
Net Sales Rs m28,715550,976 5.2%  
Other income Rs m545-3,212 -17.0%   
Total revenues Rs m29,260547,765 5.3%   
Gross profit Rs m5,059137,030 3.7%  
Depreciation Rs m38040,467 0.9%   
Interest Rs m223,766 0.0%   
Profit before tax Rs m5,22269,586 7.5%   
Minority Interest Rs m0-285 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,8922,926 64.7%   
Profit after tax Rs m3,50866,374 5.3%  
Gross profit margin %17.624.9 70.8%  
Effective tax rate %36.24.2 861.6%   
Net profit margin %12.212.0 101.4%  
BALANCE SHEET DATA
Current assets Rs m21,815484,381 4.5%   
Current liabilities Rs m15,999378,689 4.2%   
Net working cap to sales %20.319.2 105.6%  
Current ratio x1.41.3 106.6%  
Inventory Days Days6478 81.5%  
Debtors Days Days19107 17.4%  
Net fixed assets Rs m12,475127,467 9.8%   
Share capital Rs m84719,484 4.3%   
"Free" reserves Rs m19,7260-   
Net worth Rs m20,573273,890 7.5%   
Long term debt Rs m6409,164 0.0%   
Total assets Rs m39,4751,103,202 3.6%  
Interest coverage x2,612.03.9 66,498.2%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.70.5 145.6%   
Return on assets %8.98.2 108.8%  
Return on equity %17.124.2 70.4%  
Return on capital %26.213.6 192.7%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-6,8650-   
CASH FLOW
From Operations Rs m4,72872,426 6.5%  
From Investments Rs m-1,042-57,117 1.8%  
From Financial Activity Rs m-3,066-19,084 16.1%  
Net Cashflow Rs m620-3,775 -16.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.37 Rs / USD

Compare GSK PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare GSK PHARMA With: STRIDES PHARMA SCIENCE  JUBILANT LIFE SCIENCES  MERCK LTD  NOVARTIS  SUN PHARMA  



Today's Market

Sensex Ends Day in Red, Oil Prices, and Top Stocks in Action Today(Pre-Open)

Share markets in India witnessed most of the selling pressure during closing hours yesterday and ended their trading session on a negative note.

Related Views On News

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 20, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS